Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

United Therapeutics (UTHR) Non Operating Income (2016 - 2025)

United Therapeutics (UTHR) has disclosed Non Operating Income for 17 consecutive years, with -$85.2 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 27.43% to -$85.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$38.5 million through Dec 2025, up 64.68% year-over-year, with the annual reading at $48.9 million for FY2025, 743.1% up from the prior year.
  • Non Operating Income hit -$85.2 million in Q4 2025 for United Therapeutics, down from $6.1 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $102.8 million in Q4 2023 to a low of -$117.4 million in Q4 2024.
  • Historically, Non Operating Income has averaged -$1.7 million across 5 years, with a median of -$950000.0 in 2022.
  • Biggest five-year swings in Non Operating Income: crashed 1796.3% in 2022 and later skyrocketed 2161.11% in 2025.
  • Year by year, Non Operating Income stood at -$33.0 million in 2021, then soared by 83.94% to -$5.3 million in 2022, then surged by 2039.62% to $102.8 million in 2023, then crashed by 214.2% to -$117.4 million in 2024, then increased by 27.43% to -$85.2 million in 2025.
  • Business Quant data shows Non Operating Income for UTHR at -$85.2 million in Q4 2025, $6.1 million in Q3 2025, and -$100000.0 in Q2 2025.